PF-AtlasКлинические испытания › NCT01968421

Prevention of OM-85 on Bronchiectasis Exacerbation

OM-85 BV · Фаза 4

ID реестра
NCT01968421
Фаза
Фаза 4
Статус
Завершено
Препарат / вмешательство
OM-85 BV
Спонсор
Chinese Academy of Medical Sciences
Начало
2015-03-01
Набор участников
196
Центры
2

Об исследовании

Non-cystic fibrosis bronchiectasis is characterized by irreversible dilatation of the medium-sized bronchi as a result of airway injury due to recurrent or chronic inflammation and infection. Bronchiectasis airways are often colonized with bacterial species. Infections of the airways are thought to play an important role in bronchiectasis exacerbation. The non-specific prevention of recurrent airway infections by immunostimulating agents has gained growing scientific interest. OM-85, consisting extracts of eight kinds of bacteria important in respiratory infections, has shown the benefit for significantly reducing the incidence of exacerbations of chronic obstructive pulmonary disease (COPD). The purpose of this study is to investigate the PReventive effect of OM-85 on Bronchiectasis Exacerbation in Chinese patients (iPROBE). This study is designed as a prospective randomised double-blind placebo-controlled multi-centred trial.

Открыть NCT01968421 на ClinicalTrials.gov →

Связанные материалы

Медицинская оговорка. Эта страница обобщает публичные данные исследования NCT01968421 только для информации. Это не медицинская рекомендация, не одобрение и не предложение участия. Проверяйте детали на ClinicalTrials.gov и у квалифицированного врача.